Research programme: cardiac gene therapies - DiNAQOR/University College London
Latest Information Update: 28 Feb 2024
At a glance
- Originator DiNAQOR AG; University College London
- Class Cardiovascular therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cardiomyopathies
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for research development in Cardiomyopathies in Switzerland (Parenteral)
- 28 Feb 2024 No recent reports of development identified for research development in Cardiomyopathies in United Kingdom (Parenteral)
- 13 Jan 2020 DiNAQOR signs collaboration and license agreement with University College London to develop cardia gene therapies